Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Neuropace Inc NPCE

Healthcare Medical Devices
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the... see more

Recent & Breaking News (NDAQ:NPCE)

NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting

GlobeNewswire 5 hours ago

NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome

GlobeNewswire 1 day ago

NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

GlobeNewswire November 12, 2024

NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy

GlobeNewswire November 4, 2024

NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024

GlobeNewswire October 22, 2024

NeuroPace Continues to Strengthen Management Team

GlobeNewswire October 16, 2024

NeuroPace Strengthens Management Team with Two Key Appointments

GlobeNewswire September 4, 2024

NeuroPace Announces Participation at Two Upcoming Healthcare Investor Conferences

GlobeNewswire August 27, 2024

NeuroPace to Participate in Upcoming Healthcare Conferences in September

GlobeNewswire August 22, 2024

NeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

GlobeNewswire August 13, 2024

NeuroPace to Report Second Quarter 2024 Financial Results on August 13, 2024

GlobeNewswire July 23, 2024

NeuroPace to Participate in Two Healthcare Conferences in May

GlobeNewswire May 14, 2024

NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 8, 2024

NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024

GlobeNewswire April 17, 2024

NeuroPace to Present at the Needham 23rd Annual Healthcare Conference

GlobeNewswire March 27, 2024

NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million

GlobeNewswire March 5, 2024

NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

GlobeNewswire February 15, 2024

NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates

GlobeNewswire January 8, 2024

NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study

GlobeNewswire December 21, 2023

NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 19, 2023